ClinicalTrials.gg
Active, not recruitingNCT06958315INSPIREUpdated Aug 7, 2026

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

An observational study in Atherosclerotic Vascular Disease and Heterozygous Familial Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 20 sites in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
219
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Atherosclerosis by Novartis — 4 open to participants now, 10 under way, 3 of them phase 3. Atherosclerosis · Novartis.

Started
2025
with 6 others
Observational
8 of 27
2 open now
Registered
22nd of 27
by date

Among the 27 studies in Atherosclerosis by Novartis, this one is one of 7 that started in 2025, is one of 8 observational ones, and was the 22nd registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

4 of the 27 studies in Atherosclerosis by Novartis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Atherosclerosis by Novartis, or all of them as a file.
02

Study summary

This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain.

Read the detailed description

The objective of the study is to determine the proportion of Atherosclerotic cardiovascular disease (ASCVD) and/or Heterozygous Familial Hypercholesterolemia (HeFH) patients reaching low-density lipoprotein-cholesterol (LDL-C) goals according to their cardiovascular risk at 12 months after the initiation of inclisiran treatment.

The study also aims to evaluate changes in LDL-C levels, safety profile, adherence and persistence to inclisiran treatment, use of concomitant lipid-lowering therapy (LLT), and patient satisfaction with inclisiran among other variables collected in clinical practice.

This is a non-interventional, prospective, multicentric, and nationwide study that will be conducted in routine clinical practice in Spain. This study will consist of three visits, coinciding with those conducted as part of the patients' routine follow-up, without interfering with the clinical practice of the participating centers. A blood test to assess LDL-C levels will be conducted at 3, 6, 9 and 12 months after inclisiran initiation, according to clinical practice.

03

Conditions studied

  • Atherosclerotic Vascular Disease
  • Heterozygous Familial Hypercholesterolemia

Browse trials for

Keywords

  • inclisiran
  • Leqvio®
  • atherosclerotic vascular disease
  • heterozygous familial hypercholesterolemia
  • Spanish clinical practice
  • Spain
  • INSPIRE
  • LDL-C goal attaiment
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥18 years) with a confirmed clinical indication for inclisiran.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years.
  2. Written signed form (ICF).
  3. Patients with a confirmed clinical indication for inclisiran who have received the first dose of inclisiran, following clinical judgement, at least 2 months prior to the inclusion in the study.
  4. Available assessment of LDL-C levels (mg/dL) within 6 months before inclisiran initiation. The measurement of LDL-C levels must be done after one month of stable LLT and without any modification from the testing up to inclisiran initiation.
  5. Statin-intolerant patients are eligible if they had documented side effects on ≥2 statins, including one at the lowest dose.

Exclusion criteria

Exclusion Criteria:

1. Participating in a clinical trial of a treatment that could modify LDL-C levels during the observational period of the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
219 participants (actual)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • Inclisiran

    Adults (≥18 years) with a confirmed clinical indication for inclisiran.

    Other: Inclisiran

Interventions

  • OtherInclisiran

    This is an observational study, there is no treatment allocation.

    Also known as: KJX839 Leqvio

06

What researchers measure

Primary outcomes

  1. LDL-C levels - 12 months

    Proportion of participants reaching guideline-established low densitiy lipoprotein-Cholesterol (LDL-C) targets according to their Cardiovascular (CV) risk * LDL-C \<55 mg/dL for ASCVD participants. * LDL-C \<70 mg/dL for HeHF patients.

    Time frame: 12 months following the initiation of inclisiran treatment.

Secondary outcomes

  1. LDL-C levels - 6 months

    Proportion of participants reaching guideline-established LDL-C targets according to their CV risk * LDL-C \<55 mg/dL for ASCVD participants. * LDL-C \<70 mg/dL for HeHF patients.

    Time frame: 6 months following the initiation of inclisiran treatment

  2. non-HLDL-C levels

    Proportion of participants with hypertriglyceridemia (triglycerides \>400 mg/dL) reaching guideline-established non-HDL-C targets according to their CV risk * Non-HDL-C \<85 mg/dL for ASCVD patients. * Non-HDL-C \<100 mg/dL for HeHF patients.

    Time frame: 6 and 12 months following the initiation of inclisiran treatment

  3. Changes from baseline in LDL-C

    Change from baseline to mean LDL-C in PCSK9i naïve patients and patients pre-treated with PCSK9i, separately.

    Time frame: Baseline, 3, 6, 9 and 12 months following the initiation of inclisiran treatment

  4. Frequency of AEs

    Incidence of AEs including, number of cardiovascular events, revascularizations, emergency visits, and hospitalizations qualifying and reported as AEs.

    Time frame: From inclisiran initiation up to 12 months post-initiation

  5. Adherence rate to the concomitant LLT treatment

    Number of participants with a Morisky Medication Adjerence Slace (MMAS) of over 80%To describe the utilization and adherence to concomitant LLT during inclisiran treatment.

    Time frame: From 1st visit up to 12 months after inclisiran initiation

  6. Proportion of participants adhering to the prescribed inclisiran dosing schedule

    To evaluate treatment adherence to inclisiran during the study period.

    Time frame: From 1st visit up to 12 months after inclisiran initiation

  7. Inclisiran reasons for non-persistence

    Number of participants by reasons for non- persistence

    Time frame: From 1st visit up to 12 months after inclisiran initiation

  8. Lp(a)

    Proportion of participants with Lp(a) ≥50 mg/dL (≥125 nmol/L), ≥70 mg/dL (≥175 nmol/L), ≥90 mg/dL (≥225 nmol/L).

    Time frame: When available, from baseline up to 12 months after inclisiran initiation

  9. Changes in Lp(a)

    To describe changes in Lp(a) at any time after inclisiran treatment, only in patients tested by clinical judgment.

    Time frame: From inclisiran initiation up to 12 months post-initiation

  10. Patient satisfaction with inclisiran, score on TSQM-II

    Treatment Satisfaction Questionnaire for Medication II evaluates satisfaction with treatment effectiveness, side effects, convenience, and global satisfaction. The TSQM-II consists of 11 items, each with 7 response options. Scores for each domain are calculated by averaging responses, transformed to a 0-100 scale, where higher scores indicate greater satisfaction

    Time frame: 3 and at 12 months after treatment initiation.

  11. Specialty of the health care profesional prescribing inclisiran

    To describe prescribing specialty.

    Time frame: From 1st visit up to 12 months after inclisiran initiation

  12. HCP who administers inclisiran

    To describe, HCP that administer inclisiran

    Time frame: From 1st visit up to 12 months after inclisiran initiation

  13. Site of treatment administration for each dose

    To describe site of treatment administration (primary, secondary or tertiary hospital, primary care center)

    Time frame: From 1st visit up to 12 months after inclisiran initiation

07

Study locations

20 sites
  • Novartis Investigative Site
    Cadiz, Andalusia 11009, Spain
  • Novartis Investigative Site
    Granada, Andalusia 18014, Spain
  • Novartis Investigative Site
    Huelva, Andalusia 21005, Spain
  • Novartis Investigative Site
    Jaén, Andalusia 23007, Spain
  • Novartis Investigative Site
    Marbella, Andalusia 29600, Spain
  • Novartis Investigative Site
    Mallorca, Balearic Islands 07198, Spain
  • Novartis Investigative Site
    Puerto Real, Cadiz 11510, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Andújar, Jaen 23740, Spain
  • Novartis Investigative Site
    Logroño, La Rioja 26006, Spain
  • Novartis Investigative Site
    San Cristóbal de La Laguna, Santa Cruz De Tenerife 38320, Spain
  • Novartis Investigative Site
    Burgos, 09006, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Fuerteventura, 35600, Spain
  • Novartis Investigative Site
    Las Palmas GC, 35010, Spain
  • Novartis Investigative Site
    León, 24080, Spain
  • Novartis Investigative Site
    Málaga, 29010, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain
  • Novartis Investigative Site
    Seville, 41009, Spain
  • Novartis Investigative Site
    Seville, 41013, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.

Of 170 observational studies under Atherosclerosis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 153. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 6, 2025
StartActual
Jun 16, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06958315
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Jun 16, 2025
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Aug 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion